ArticleCancers2026
Angiogenesis-Informed Preoperative CT Radiogenomics Predicts Overall Survival in Clear Cell Renal Cell Carcinoma: Development and External Validation.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND/
objectivesWe aimed to identify angiogenesis-related prognostic biomarkers and develop a radiogenomics model to predict overall survival (OS) in clear cell renal cell carcinoma (ccRCC), supporting risk stratification and potential therapeutic target discovery.
methodsBulk transcriptomes from The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma cohort (TCGA-KIRC), seven Gene Expression Omnibus (GEO) microarrays, and a single-cell RNA sequencing (scRNA-seq) dataset were integrated to identify angiogenesis-related prognostic genes. Preoperative contrast-enhanced computed tomography (CT) images from The Cancer Imaging Archive Kidney Renal Clear Cell Carcinoma collection (TCIA-KIRC) were used for radiomics feature extraction, and a radiogenomics signature was constructed by linking radiomic features with transcriptomic risk patterns. Nine machine learning models were trained to predict OS; the best model was further evaluated in an independent external retrospective cohort. PDLIM1 (PDZ and LIM domain protein 1) was validated at the protein level, and conditioned medium from stable ccRCC cell lines was applied to human umbilical vein endothelial cells (HUVECs) for Matrigel tube formation assays.
resultsFive angiogenesis-related hub genes (PDLIM1, EMCN, ARPC1B, PLAT, and TIMP1) were identified. The extreme gradient boosting (XGBoost)-based radiogenomics model showed the best performance, with time-dependent concordance index (C-index) values of 0.880, 0.816, and 0.789 at 1, 3, and 5 years in the training set and 0.864, 0.758, and 0.736 in the internal validation set, respectively. In the external validation cohort, C-index values were 0.800, 0.726, and 0.703 at 1, 3, and 5 years. PDLIM1 protein was upregulated in ccRCC versus normal tissues. Functionally, PDLIM1 overexpression suppressed, whereas PDLIM1 knockdown promoted tube formation.
conclusionsThis study developed and validated an angiogenesis-related radiogenomics model that accurately predicts OS in ccRCC patients and provides potential therapeutic targets for anti-angiogenic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.